BioMarin Pharmaceutical completed its $4.8 billion acquisition of Amicus Therapeutics, adding key rare disease treatments Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease to its portfolio. This acquisition strengthens BioMarin's position in lysosomal storage diseases and expands its commercial reach globally. BioMarin also gains U.S. rights to DMX-200, a potential treatment for a rare kidney disease, enhancing its pipeline. The company plans to update its 2026 financial guidance during its Q1 earnings call on May 4, 2026.
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
Bitcoin miners are experiencing declining revenue as the network's hash rate and mining difficulty fall, reflecting a shift of miners into AI infrastructure. Despite this stress, miners are accumulating Bitcoin, with reserves increasing by 1%, signal...
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
